SORIN GROUP is a global medical device company and a leader in the treatment of cardiovascular diseases.
The Company develops, manufactures and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders.

Over 40 years of excellence in Research and Development.

We devote $70.1 million to R&D, accounting for over 9,4% of sales.

15% of our employees (over 500 people) work in R&D in centers in North America, France, Italy and Germany.

Our multidisciplinary teams bring together researchers from different backgrounds to offer a broad range of technical and scientific expertise.Our “Engineer-Physician intelligence Networks” provide a continuous source of knowledge and ideas in order to develop innovative therapeutic solutions for patients and healthcare professionals.

We have forged partnerships with cardiology specialists at world renowned universities and research centers across the globe.Our portfolio contains over 2,000 patents.

sorin logo

SafeR function


99.9% intrinsic conduction1

Intelligent Management of AV Conduction

  • Ensures DDD pacing when needed for ALL types of AV block
  • Provides AAI pacing while continuously monitoring AV conduction
  • Switches back to AAI mode when possible

safeR sorin

Manages all AV Block : AAI --> DDD

  • AVB I : 6 long PR intervals --> DDD

safeR sorin

  • AVB II : 3 blocked atrial events within the last 12 cycles -->DDD

safeR sorin

  • AVB III : 2 consecutive blocked atrial events -->DDD

safeR sorin


  • After 12 consecutive spontaneous ventricular events (R waves)
  • Automatically every 100 paced ventricular cycles (if native AV conduction is not resumed the device switches again in DDD mode using one of the criteria listed above)


Manages Rest and Exercise

  • AVB I criteria can be suppressed at rest
  • Rapid switch to DDD during exercise if required


Manages Day and Night

  • Reduces nocturnal pacing by allowing long PR
  • Tests for AV conduction each morning if in DDD

Intended uses, warnings and precautions

1. Anselme et al. First clinical results of AAIsafeR2, a new mode to prevent ventricular pacing. Heart Rhythm 2006; 2, supp 5; p4-99 (abs).